[{"orgOrder":0,"company":"Invios","sponsor":"Dana-Farber Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"INV501","moa":"Tumor growth","graph1":"Oncology","graph2":"Preclinical","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invios \/ Dana-Farber Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Invios \/ Dana-Farber Cancer Institute"},{"orgOrder":0,"company":"Invios","sponsor":"Austrian Research Promotion Agency","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"APN401","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invios \/ Austrian Research Promotion Agency","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Austrian Research Promotion Agency"},{"orgOrder":0,"company":"Invios","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Series A Financing","leadProduct":"INV501","moa":"Tumor growth","graph1":"Oncology","graph2":"Preclinical","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invios \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Invios \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Invios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"APN401","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Invios \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Inapplicable"},{"orgOrder":0,"company":"Invios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"INV501","moa":"Tumor growth","graph1":"Oncology","graph2":"Preclinical","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Invios \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Invios \/ Inapplicable"},{"orgOrder":0,"company":"Invios","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"APN401","moa":"CBL-B","graph1":"Oncology","graph2":"Phase I","graph3":"Invios","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Invios \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Invios \/ Inapplicable"}]